Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis

Blood Pressure

Volumn 26, Issue 3, 2017, Pages 139-149

  Yuan, Wenming ^a   Cheng, Genyang ^a   Li, Bin ^a   Li, Yansheng ^a   Lu, Shan ^a   Liu, Dong ^a   Xiao, Jing ^a   Zhao, Zhanzheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

24 hour ambulatory blood pressure; Endothelin receptor antagonist; hypertension; meta analysis

Indexed keywords

ATRASENTAN; AVOSENTAN; BOSENTAN; DARUSENTAN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; TEZOSENTAN; ANTIHYPERTENSIVE AGENT; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SULFONAMIDE; TETRAZOLE DERIVATIVE;

ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FOLLOW UP; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; LUNG EDEMA; META ANALYSIS; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SEVERE HEPATIC IMPAIRMENT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; STATISTICAL MODEL; SURVIVAL ANALYSIS;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; HYPERTENSION; MIDDLE AGED; MODELS, STATISTICAL; PHENYLPROPIONATES; PYRIDINES; PYRIMIDINES; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; SURVIVAL ANALYSIS; TETRAZOLES;

EID: 84994180721     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037051.2016.1208730     Document Type: Article

References (38)

1. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–520.
2. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension:diagnosis, evaluation, and treatment. A scientific statement from the American heart association professional education committee of the council for high blood pressure research. Hypertension. 2008;51:1403–1419.
3. Kohan DE., Endothelin, hypertension and chronic kidney disease:new insights. Curr Opin Nephrol Hypertens. 2010;19:134–139.
4. Da SA, Kuo JJ, Tallam LS, et al. Role of endothelin-1 in blood pressure regulation in a rat model of visceral obesity and hypertension. Hypertension. 2004;43:383–387.
5. Donato AJ, Lesniewski LA, Stuart D, et al. Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development. Life Sci. 2014;118:238–243.
6. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension:a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423–1431.
7. Nakov R, Pfarr E, Eberle S., Darusentan:an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens. 2002;15:583–589.
8. Schreuder THA, Duncker DJ, Hopman MTE, et al. Randomized controlled trial using bosentan to enhance the impact of exercise training in subjects with type 2 diabetes mellitus. Exp Physiol. 2014;99:1538–1547.
9. Rafnsson A, Bohm F, Settergren M, et al. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria:a randomised trial. Diabetologia. 2012;55:600–607.
10. Spence S, Anderson C, Cukierski M, et al. Teratogenic effects of the endothelin receptor antagonist L-753,037 in the rat. Reprod Toxicol. 1999;13:15–29.
11. Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21:527–535.
12. Higgins JPT, Green S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]:Cochrane Collabor 2011.
13. DerSimonian R, Kacker R., Random-effects model for meta-analysis of clinical trials:an update. Contemp Clin Trials. 2007;28:105–114.
14. Review Manager (RevMan) [Computer program]. Version 5.3.Copenhagen:The Nordic Cochrane Centre. Cochrane Collabor 2014.
15. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
16. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart failure (EARTH):randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347–354.
17. Bergler-Klein J, Pacher R, Berger R, et al. Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure. J Heart Lung Transplant. 2004;23:20–27.
18. Cotter G, Kaluski E, Stangl K, et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail. 2004;6:601–609.
19. Raichlin E, Prasad A, Mathew V, et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension. 2008;52:522–528.
20. Schalcher C, Cotter G, Reisin L, et al. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J. 2001;142:340–349.
21. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98:2262–2268.
22. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2003;42:140–147.
23. de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25:1083–1093.
24. Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22:763–772.
25. Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures:report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824–830.
26. Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension:results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007;9:760–769.
27. Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators. N Engl J Med. 1998;338:784–790.
28. Wenzel RR, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol. 2009;20:655–664.
29. Rosenthal R., The “file drawer” problem and tolerance for null results. Psychol Bull. 1979;86:638–641.
30. Donckier J, Stoleru L, Hayashida W, et al. Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation. 1995;92:106–113.
31. Lin H, Smith MJ, Young DB., Roles of prostaglandins and nitric oxide in the effect of endothelin-1 on renal hemodynamics. Hypertension. 1996;28:372–378.
32. Plato CF, Pollock DM, Garvin JL., Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release. Am J Physiol Renal Physiol. 2000;279:F326–333.
33. Ge Y, Bagnall A, Stricklett PK, et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol. 2006;291:F1274–1280.
34. Dieterle W, Hengelage T., Absolute bioavailability and pharmacokinetics of avosentan in man. Int J Clin Pharmacol Ther. 2009;47:587–594.
35. Dingemanse J, van Giersbergen PL., Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43:1089–1115.
36. Nakano D, Pollock DM., Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension. 2009;53:324–330.
37. Zhang HD, Zhang R, Jiang X, et al. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension:a systematic review and meta-analysis. Am Heart J. 2015;170:96–103.
38. Yuan W, Li Y, Wang J, et al. Endothelin-receptor antagonists for diabetic nephropathy:a meta-analysis. Nephrology (Carlton). 2015;20:459–466.